CCMEP™ is the only credential that designates qualified individuals as Certified CME Professionals.


Test Development in
collaboration with:

Buy Tarceva (Erlotinib) tablets online on NCCME

How and where to order Erlotinib HCl (Tarceva) 150 mg tablets online:

Shop:MEDS FOR SALE
Prices:from $34.30 per pill
Discount:5% coupon: 5OFF
Forms:Tarceva (Erlotinib Hydrochloride) 150 mg tablets
Quantity:30 bottles
Type:Erlotinib brand, Erlonat brand, Tarceva generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Indications and usage:

  • Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
  • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.


    Contraindications:

    None.


    Dosage and administration:

  • The dose for NSCLC is 150 mg/day.
  • The dose for pancreatic cancer is 100 mg/day.
  • All doses of Tarceva should be taken on an empty stomach at least one hour before or two hours after food.
  • Reduce in 50 mg decrements, when necessary.


    Dosage forms and strengths:

    Tarceva (Erlotinib Hydrochloride) film-coated tablets for oral use: 25 mg, 100 mg, and 150 mg.


    Overdosage:

    Withhold erlotinib in patients with an overdose or suspected overdose and institute symptomatic treatment.


    Warnings and precautions:

  • Interstitial lung disease (ILD): Occurs in 1.1% of patients. Withhold Tarceva for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.
  • Renal failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Tarceva for severe renaltoxicity.
  • Hepatotoxicity: Occurs with or without hepatic impairment, including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Tarceva (Erlotinib Hydrochloride) for severe or worsening liver tests.
  • Gastrointestinal perforations: Discontinue this drug.
  • Bullous and exfoliative skin disorders: Discontinue Tarceva.
  • Cerebrovascular accident (CVA): The risk of CVA is increased in patients with pancreatic cancer.
  • Microangiopathic hemolytic anemia (MAHA): The risk of MAHA is increased in patients with pancreatic cancer.
  • Ocular disorders: Discontinue this medication for corneal perforation, ulceration or persistent severe keratitis.
  • Hemorrhage in patients taking warfarin: Regularly monitor INR in patients taking warfarin or other coumarin-derivative anticoagulants.
  • Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.


    Drug interactions:

  • CYP3A4 inhibitors or a combined CYP3A4 and CYP1A2 inhibitor increase erlotinib plasma concentrations. Avoid concomitant use. If not possible, reduce Tarceva dose.
  • CYP3A4 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Erlotinib dose.
  • Cigarette smoking and CYP1A2 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Tarceva dose.
  • Drugs that increase gastric pH decrease erlotinib plasma concentrations. For proton pump inhibitors avoid concomitant use if possible. For H-2 receptor antagonists, take this medicine 10 hours after H-2 receptor antagonist dosing. For use with antacids, separate dosing by several hours.

    Related medications:

    Sorafenib (Nexavar)


    Use in specific populations:

    Lactation: Do not breastfeed.


    Adverse reactions, side effects:

  • The most common adverse reactions (>20%) in maintenance treatment are rash-like events and diarrhea.
  • The most common adverse reactions (>20%) in 2nd line NSCLC are rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection and vomiting.
  • The most common adverse reactions (>20%) in pancreatic cancer are fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis and myalgia.


    Where to buy erlotinib online:

    To purchase Erlotinib HCl (Tarceva) 150 mg tablets from reliable online pharmacies and drugstores please use resources described above on this webpage.

  •  
    About Us | Contact Us | © 2006 - 2022 NCCME (NC-CME)